Originally published as JCO Early Release 10.1200/JCO.2007.13.9881 on January 2 2008

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roach, M. Articles by Pilepich, M. V. Search for Related Content PubMed PubMed Citation Articles by Roach, M., III Articles by Pilepich, M. V. Social Bookmarking                            What's this?

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

Mack Roach, III, Kyounghwa Bae, Joycelyn Speight, Harvey B. Wolkov, Phillip Rubin, R. Jeffrey Lee, Colleen Lawton, Richard Valicenti, David Grignon, Miljenko V. Pilepich

From the Departments of Radiation Oncology and Urology, University of California San Francisco, San Francisco; Radiation Oncology Center, Sutter Cancer Center, Sacramento; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA; University of Rochester, Medical Center, Rochester, NY; Latter-Day Saints Hospital Radiation Center, Salt Lake City, UT; Medical College of Wisconsin Department of Radiation Oncology, Milwaukee, WI; Radiation Therapy Oncology Group Department of Statistics; and Department of Radiation Oncology, Thomas Jefferson University Hospital, Bodine Cancer Center, Philadelphia, PA; and Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN

Corresponding author: Mack Roach III, MD, University of California San Francisco, 1600 Divisadero St, Suite H1031, San Francisco, CA 94143-1708; e-mail: mroach{at}radonc.ucsf.edu

Purpose Radiation Therapy Oncology Group (RTOG) 8610 was the first phase III randomized trial to evaluate neoadjuvant androgen deprivation therapy (ADT) in combination with external-beam radiotherapy (EBRT) in men with locally advanced prostate cancer. This report summarizes long-term follow-up results.

Materials and Methods Between 1987 and 1991, 456 assessable patients (median age, 70 years) were enrolled. Eligible patients had bulky (5 x 5 cm) tumors (T2-4) with or without pelvic lymph node involvement according to the 1988 American Joint Committee on Cancer TNM staging system. Patients received combined ADT that consisted of goserelin 3.6 mg every 4 weeks and flutamide 250 mg tid for 2 months before and concurrent with EBRT, or they received EBRT alone. Study end points included overall survival (OS), disease-specific mortality (DSM), distant metastasis (DM), disease-free survival (DFS), and biochemical failure (BF).

Results Ten-year OS estimates (43% v 34%) and median survival times (8.7 v 7.3 years) favored ADT and EBRT, respectively; however, these differences did not reach statistical significance (P = .12). There was a statistically significant improvement in 10-year DSM (23% v 36%; P = .01), DM (35% v 47%; P = .006), DFS (11% v 3%; P < .0001), and BF (65% v 80%; P < .0001) with the addition of ADT, but no differences were observed in the risk of fatal cardiac events.

Conclusion The addition of 4 months of ADT to EBRT appears to have a dramatic impact on clinically meaningful end points in men with locally advanced disease with no statistically significant impact on the risk of fatal cardiac events.

published online ahead of print at www.jco.org on January 2, 2008.

Supported by Grants No. Radiation Therapy Oncology Group U10 CA21661, CCOP U10 CA37422, and Stat U10 CA32115 from the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. V. D'Amico and M.-H. Chen Pretreatment Prostate-Specific Antigen Velocity and the Risk of Death From Prostate Cancer in the Individual With Low-Risk Prostate Cancer J. Clin. Oncol., August 1, 2009; 27(22): 3575 - 3576. [Full Text] [PDF]

				S. M.H. Alibhai, M. Duong-Hua, R. Sutradhar, N. E. Fleshner, P. Warde, A. M. Cheung, and L. F. Paszat Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes J. Clin. Oncol., July 20, 2009; 27(21): 3452 - 3458. [Abstract] [Full Text] [PDF]

				W. Dale "Staging the Aging" When Considering Androgen Deprivation Therapy for Older Men With Prostate Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3420 - 3422. [Full Text] [PDF]

				M. Bolla, T. M. de Reijke, G. Van Tienhoven, A. C.M. Van den Bergh, J. Oddens, P. M.P. Poortmans, E. Gez, P. Kil, A. Akdas, G. Soete, et al. Duration of Androgen Suppression in the Treatment of Prostate Cancer N. Engl. J. Med., June 11, 2009; 360(24): 2516 - 2527. [Abstract] [Full Text] [PDF]

				P. J. Saylor and M. R. Smith Prostate Cancer Survivorship: Metabolic Complications of Androgen Deprivation Therapy ASCO Educational Book, January 1, 2009; 2009(1): 263 - 268. [Abstract] [Full Text] [PDF]